glioblastoma - Articles and news items

First patient treated in Phase I VXM01 glioblastoma trial

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Vaximm’s VXM01 is a oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells…

Scientists to progress glioblastoma antibody into clinical trials

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

With funding amounting to €3.5 million, the molecule, called 6A10, shall undergo the first phase of clinical testing…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+